2024
Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation
May C, Noble P, Herzog E, Meffre E, Hansen J. Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation. Biochemical And Biophysical Research Communications 2024, 720: 150123. PMID: 38759301, DOI: 10.1016/j.bbrc.2024.150123.Peer-Reviewed Original ResearchDiffuse cutaneous systemic sclerosisCutaneous systemic sclerosisAnti-topoisomerase 1Systemic lupus erythematosusDiscovery of autoantibodiesMechanisms of autoimmunityInhibit DNA repairScleroderma autoantibodiesScleroderma subtypeSystemic sclerosisLupus erythematosusAutoantibodiesCancer therapyPathophysiologyReagent resourcesCellular dysfunctionAntibodiesCell nucleiDNA repair
2022
Inhibition of NETosis by a Nuclear-Penetrating Anti-DNA Autoantibody
Chen X, Cuffari BJ, Dubljevic V, Shirali A, Zhou J, Campbell JA, Suits SC, O'Sullivan KM, Hansen JE. Inhibition of NETosis by a Nuclear-Penetrating Anti-DNA Autoantibody. ImmunoHorizons 2022, 6: 356-365. PMID: 35697479, DOI: 10.4049/immunohorizons.2100091.Peer-Reviewed Original ResearchConceptsNeutrophil extracellular trapsAnti-DNA autoantibodiesRelease of NETsInhibition of NETosisOncology clinical trialsDifferentiated PLB-985 cellsMechanisms of NETosisCalcium ionophore ionomycinPLB-985 cellsIndependent NETosisC57BL/6 miceClinical trialsExtracellular trapsSuch AbsAutoantibodiesNeutrophil biologyDNA damage responseTherapeutic potentialNETosisHistone citrullinationIonophore ionomycinWestern blotSignificant inhibitionMultiple diseasesNeutrophils
2021
ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody
Rattray Z, Deng G, Zhang S, Shirali A, May CK, Chen X, Cuffari BJ, Liu J, Zou P, Rattray N, Johnson CH, Dubljevic V, Campbell JA, Huttner A, Baehring JM, Zhou J, Hansen JE. ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody. JCI Insight 2021, 6: e145875. PMID: 34128837, PMCID: PMC8410084, DOI: 10.1172/jci.insight.145875.Peer-Reviewed Original ResearchConceptsBlood-brain barrierAnti-DNA autoantibodiesBrain tumorsBreast cancer brain metastasesBlood-brain barrier transportBrain tumor immunotherapyCancer brain metastasesBrain endothelial cellsEndothelial cell penetrationCNS lupusNeurotoxic autoantibodiesBrain metastasesTumor immunotherapyBarrier transportAntibody-based approachesCNS penetrationAutoantibodiesEfficacy studiesOrthotopic glioblastomaEndothelial cellsTumorsCancer cellsNucleoside fluxesActionable mechanismsKey transporters
2015
DNA-dependent targeting of cell nuclei by a lupus autoantibody
Weisbart RH, Chan G, Jordaan G, Noble PW, Liu Y, Glazer PM, Nishimura RN, Hansen JE. DNA-dependent targeting of cell nuclei by a lupus autoantibody. Scientific Reports 2015, 5: 12022. PMID: 26156563, PMCID: PMC4496662, DOI: 10.1038/srep12022.Peer-Reviewed Original ResearchConceptsLupus anti-DNA autoantibodiesAnti-DNA autoantibodiesTumor cell nucleiSingle-chain variable fragmentPotential therapeutic applicationsLupus autoantibodiesTherapeutic approachesIschemic conditionsCertain cancer cellsChain variable fragmentCancer cellsCell nucleiAutoantibodiesNecrotic regionsVariable fragmentTherapeutic applicationsDNA damageNuclear uptakeScFvMalignancyGreater understandingTumorsStrokeDiseaseOptimizing a Lupus Autoantibody for Targeted Cancer Therapy
Noble PW, Chan G, Young MR, Weisbart RH, Hansen JE. Optimizing a Lupus Autoantibody for Targeted Cancer Therapy. Cancer Research 2015, 75: 2285-2291. PMID: 25832653, DOI: 10.1158/0008-5472.can-14-2278.Peer-Reviewed Original Research
2014
A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells
Noble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Scientific Reports 2014, 4: 5958. PMID: 25091037, PMCID: PMC5380011, DOI: 10.1038/srep05958.Peer-Reviewed Original ResearchConceptsLupus autoantibodiesTherapeutic agentsCancer cellsSystemic lupus erythematosusBRCA2-deficient cellsLupus erythematosusBRCA2-deficient cancer cellsDLD1 colon cancer cellsColon cancer cellsSuch antibodiesLower riskAutoantibodiesSpecific cancersAntibodiesMalignancyDifferential effectsToxic effectsPotential utilityCellsAgentsFurther supportDNA-damaging agentsErythematosusTherapyCancer
2012
Targeting Cancer with a Lupus Autoantibody
Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. Targeting Cancer with a Lupus Autoantibody. Science Translational Medicine 2012, 4: 157ra142. PMID: 23100628, PMCID: PMC3713477, DOI: 10.1126/scitranslmed.3004385.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAnti-DNA antibodiesLupus autoantibodiesProstate cancerCancer therapyLupus anti-DNA antibodiesHuman tumor xenograftsDNA-damaging therapiesCultured tumor cellsSLE patientsLupus erythematosusSLE pathophysiologyAutoimmune diseasesDose doxorubicinTumor xenograftsAutoantibodiesHuman cancer cellsTherapyTherapeutic agentsTumor cellsCancerCancer cellsLupusMalignancyPrecise role